急诊科脓毒症医嘱套餐设计与哌拉西林-他唑巴坦第二剂给药延迟的关联
这项回顾性队列研究在11家医院开展,纳入两年内经急诊脓毒症医嘱套餐开具至少一剂哌拉西林-他唑巴坦的成人患者,排除接受少于两剂者。研究期中点将全系统急诊脓毒症医嘱套餐从一次性剂量更新为包含按计划抗生素频次,比较更新前一年(1222例)与更新后一年(1997例)两个队列。主要结局为重大延迟(给药延迟超过推荐给药间隔的25%),更新后组重大第二剂延迟比例显著更低(32.7% vs 25.6%,p<0.01;校正OR 0.64,95%CI 0.52至0.78)。中断时间序列分析未发现每月重大延迟频率斜率组间差异,但存在显著水平变化(更新后变化-10%,95%CI -17.9%至-1.9%)。作者认为在急诊脓毒症医嘱套餐中纳入按计划抗生素频次是减少第二剂抗生素延迟的务实机制。
要点
- 更新后组重大第二剂延迟比例32.7% vs 25.6%,显著更低(p<0.01;校正OR 0.64,95%CI 0.52至0.78)。
- 重大延迟定义为给药延迟超过推荐给药间隔的25%。
- 中断时间序列分析:每月重大延迟频率斜率无组间差异,但水平变化显著(更新后变化-10%,95%CI -17.9%至-1.9%)。
- 研究纳入11家医院成人患者,排除接受少于两剂哌拉西林-他唑巴坦者。
- 作者认为在急诊脓毒症医嘱套餐中纳入按计划抗生素频次是减少第二剂延迟的务实机制。
适用人群与场景
- 在11家医院急诊科接受治疗、至少有一剂哌拉西林-他唑巴坦经急诊脓毒症医嘱套餐开具的成人患者。
- 排除接受少于两剂哌拉西林-他唑巴坦的患者。
诊断标准与关键阈值
- 重大延迟:给药延迟超过推荐给药间隔的25%。
研究设计与关键结果
- 研究类型:回顾性队列研究,在大型整合医疗系统的11家医院开展,研究期两年。
- 研究期中点将全系统急诊脓毒症医嘱套餐从一次性剂量更新为包含按计划抗生素频次。
- 共纳入3219例患者:更新前组1222例,更新后组1997例。
- 主要结局:更新后组重大第二剂延迟比例显著低于更新前组(32.7% vs 25.6%,p<0.01;校正OR 0.64,95%CI 0.52至0.78)。
- 中断时间序列分析:每月重大延迟频率斜率无组间差异,但存在显著水平变化(更新后变化-10%,95%CI -17.9%至-1.9%)。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在急诊脓毒症医嘱套餐中纳入按计划抗生素频次是减少第二剂抗生素延迟的务实机制。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Delay to first antibiotic dose in patients with sepsis has been associated with increased mortality. Second dose antibiotic delay has also been linked to worsened patient outcomes. Optimal methods to decrease second dose delay are currently unclear. The primary objective of this study was to evaluate the association between updating an emergency department (ED) sepsis order set design from one-time doses to scheduled antibiotic frequencies and delay to administration of second piperacillin-tazobactam dose.
METHODS: This retrospective cohort study was conducted at eleven hospitals in a large, integrated health system and included adult patients treated in the ED with at least one dose of piperacillin-tazobactam ordered through an ED sepsis order set over a two year period. Patients were excluded if they received less than two doses of piperacillin-tazobactam. Midway through the study period, the enterprise-wide ED sepsis order set was updated to include scheduled antibiotic frequencies. Two patient cohorts receiving piperacillin-tazobactam were compared: those in the year before the order set update and those in the year post-update. The primary outcome was major delay, defined as an administration delay >25% of the recommended dosing interval, which was evaluated with multivariable logistic regression and interrupted time series analysis.
RESULTS: 3219 patients were included: 1222 in the pre-update group and 1997 in the post-update group. The proportion of patients who experienced major second dose delay was significantly lower in the post-update group (32.7% vs 25.6%, p < 0.01; adjusted OR 0.64, 95% CI 0.52 to 0.78). No between-group difference was detected in the slope of monthly major delay frequency, but there was a significant level change (post-update change -10%, 95% CI -17.9% to -1.9%).
CONCLUSIONS: Including scheduled antibiotic frequencies in ED sepsis order sets is a pragmatic mechanism to decrease delays in second antibiotic doses.
参考来源
- Erickson RM, Sacha GL, Bauer SR, et al. Association between emergency department sepsis order set design and delay to second dose piperacillin-tazobactam administration. Am J Emerg Med. 2023. PMID: 36801535. doi:10.1016/j.ajem.2023.01.057
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。